PT - JOURNAL ARTICLE AU - Roeder, Alexa J. AU - Koehler, Megan A. AU - Svarovsky, Sergei AU - Jasbi, Paniz AU - Seit-Nebi, Alim AU - Gonzalez-Moa, Maria J. AU - Vanderhoof, John AU - McKechnie, Davis AU - Edwards, Baylee A. AU - Lake, Douglas F. TI - SARS-CoV-2 Omicron Variant Infection of Individuals with High Titer Neutralizing Antibodies Post-3<sup>rd</sup> mRNA Vaccine Dose AID - 10.1101/2022.03.03.22270812 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.03.22270812 4099 - http://medrxiv.org/content/early/2022/03/06/2022.03.03.22270812.short 4100 - http://medrxiv.org/content/early/2022/03/06/2022.03.03.22270812.full AB - Background Vaccination with COVID-19 mRNA vaccines prevent hospitalization and severe disease caused by wildtype SARS-CoV-2 and several variants, and likely prevented infection when serum neutralizing antibody (NAb) titers were &gt;1:160. Preventing infection limits viral replication resulting in mutation, which can lead to the emergence of additional variants.Methods During a longitudinal study to evaluate durability of a three-dose mRNA vaccine regimen (2 primary doses and a booster) using a rapid test that semi-quantitatively measures NAbs, the Omicron variant emerged and quickly spread globally. We evaluated NAb levels measured prior to symptomatic breakthrough infection, in groups infected prior to and after the emergence of Omicron.Results During the SARS-CoV-2 Delta variant wave, 93% of breakthrough infections in our study occurred when serum NAb titers were &lt;1:80. In contrast, after the emergence of Omicron, study participants with high NAb titers that had received booster vaccine doses became symptomatically infected. NAb titers prior to infection were ≥1:640 in 64% of the Omicron-infected population, ≥1:320 (14%), and ≥1:160 (21%).Discussion These results indicate that high titers of NAbs elicited by currently available mRNA vaccines do not protect against infection with the Omicron variant, and that mild to moderate symptomatic infections did occur in a vaccinated and boosted population, although did not require hospitalization.Competing Interest StatementDFL and SS are co-founders of Sapphire, the research division of AXIM Biotechnologies. SS, MGM, and AS-N are employed by AXIM. All other authors have no competing interests to report.Funding StatementThis study was funded in part by Sapphire/AXIM Biotechnologies, Inc. (San Diego, CA). The funder had no role in the study design, collection, analysis, and interpretation of data. All authors and co-authors performed the study independent of influence of the funders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB #0601000548 of Arizona State University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript and supplementary materials. Additional data not included are available upon reasonable request to the corresponding author.